
Nutritional Intervention in IBD

Elaine Neary, BSc MINDI Senior Dietitian in Gastroenterology 7th Jan 2011



30 minute overview

- Malnutrition in IBD
- Roles of nutrition
 - Adjuvant
 - <u>Primary</u>
- Clinical evidence
- Patient selection
 - Case study
- Best practice guidelines
- Conclusion



Learning objectives



- 1. Consider the causes of malnutrition in IBD
- 2. Understand the different roles of nutrition
- 3. Learn the indications for primary therapy
- 4. Be aware of recent best practice guidelines



Questions





Can you use nutrition to treat active Crohn's Disease?

What are the important nutritional issues in this patient group?




Malnutrition in IBD





Source: Wiskin, AE, Wootton, SA and Beattie RM, 2007

Nutrient absorption sites





Nutritional status – active phase



- Up to 85% Protein Energy Malnutrition in hospitalised pts¹
- Up to 75% experience weight loss & 50% present in negative nitrogen balance²

¹ Vagianos K *et al* 2007 ² Lochs H, 2004



Nutritional status - quiescent

- 40% overweight in quiescent disease³
 - More prone to develop active CD⁴
 - Require surgery sooner⁵
- Lean body mass & muscle function are significantly reduced even in remission⁶
- Body fat distribution differs depletion of visible fat & increase in intra-abdominal fat → ? role in inflammatory process⁷

³Nic Suibhne *et al*, 2009
⁴Blain A *et al*, 2002
⁵Hass DJ *et al*, 2006
⁶Jahnsen J *et* al, 2003
⁷Peyrin-Biroulet L *et* al, 2007

Micronutrient deficiencies



Deficiency	Estimated Frequency %	
Bone related:		
Calcium	13	
 Magnesium 	14-33	
 Vitamin D 	75	
Anaemias:		
• Iron	39	
Folate	54	
• Vit B12	48	

Source: O' Sullivan MA & O Morain CA, 1998

Associated nutritional complications

- Metabolic bone disease -
- > Osteopenia/Osteoporosis/Osteomalacia
- Lactose intolerance -
 - > Transient

 \geq

- > Steatorrhoea -
 - ➤ TI involvement/excision → reduced bile acid absorption → fat & fat sol vit malabsorption (Vit ADEK)

> Micronutrient deficiencies -

- Magnesium & Zinc if excessive GI losses, Vit A, D & E, Vit B_6
- Anaemia -
 - > iron, folate, Vit B_{12}

> Thromboembolic complications -

> Excess plasma homocysteine in IBD. Pathway dependent on folate, B_{12} and B_6



Seek and treat



Role of Nutrition in IBD

Diet in IBD

- Dietary intervention depends on:
 - Disease location
 - Phase active/quiescent
 - Nature presence of strictures/fistulae
 - Current medical treatment
 - Surgical intervention
 - Individual symptoms

No clear nutrition 'formulation' that works for all patients



Adjuvant Therapy



Basic nutrition support to prevent or treat malnutrition

- Supplemental NG feeding for weight gain
- Micronutrient replacement if deficiency
- Parenteral nutrition (PN) if small bowel obstruction

For **correction and maintenance** of nutritional status in <u>both</u> Crohns and Ulcerative Colitis

Targeting nutritional status - weight, nutrient deficiencies, functionality

Primary treatment



Using nutrition to <u>achieve remission</u> in patients with an acute exacerbation of <u>Crohn's disease</u>

- Exclusive liquid diet/Total Enteral Nutrition (TEN)
- Polymeric or elemental type formula
- Orally <u>or</u> via nasogastric tube (NGT)
- Min 10 days Approx 4-6 weeks
- Commence reintroduction diet (e.g. LOFFLEX) when established on medical treatment
 - Draft British Dietetic Association (BDA) GSIG consensus guidelines 2010

Targeting disease activity & inflammation

Formulae

Categories refer to nitrogen source

Polymeric = whole protein

e.g. Osmolite (*Abbott*) Nutrison (*Nutricia*) Fresubin (*Fresenius Kabi*) Modulin IBD (*Nestle*)

Semi-elemental = polypeptides

e.g. Perative (*Abbott*) Peptisorb (*Nutricia*) Survimed OPD (Fresenius Kabi)

Elemental = amino acids

e.g. E028 (*Nutricia*)



Reintroduction diets


- Elimination diets
 - 1 new food per day, 2-3 times daily
 - Concurrent reduction in sip feed volume
 - Food diary
 - If symptom free, allow food ad libitum
 - If provokes reaction, exclude and retest later
 - 2 days rest after 7 days testing (delayed reactions)
 - Process takes ~ 3months even with daily testing
 - Continue for 2-3 symptom-free years before retesting intolerances

• 'LOFFLEX'

- 'Low fat, fibre limited, exclusion diet'
- Based on foods least likely to cause intolerance
- Start with more foods \rightarrow more acceptable
- Process takes ~ 2-4weeks



Not allowed	Allowed	
Pork, meat products	All other lean meat & poultry	
Fish in batter/crumb/tinned in oil/tomato	All other types of fish/shellfish	
Cow/sheep/goat milk, dairy products, eggs, chocolate	Soya milk & products	
Wheat, rye, barley, corn, oats, yeast	Rice, tapioca, sago, arrowroot	
Corn & vegetable oil	Sunflower & olive oils in moderation	
Pulses, onion, tomato, sweetcorn	Potato & all other veg, 2 portions a day, no skins/seeds	
Citrus, apple, banana, dried fruit	All other fruit, 2 portions per day, no skins/seeds	
Tea, coffee, alcohol, squash, cola	Fruit/herbal teas, water, ribena, non-citrus fruit juice	
Gravy mixes, salad dressings, nuts, seeds	Salt, pepper, herbs, spices, sugar, honey, jam	





Clinical Evidence


Evidence - inducing remission



 3 meta-analyses & 1 cochrane review conclude steroid therapy is more effective than liquid diets at inducing remission ^{8,9,10,11}

⁸Fernandez-Banares F *et al*, 1994
⁹Griffiths AM *et al*,1995
¹⁰Messori A *et al*,1996
¹¹Zachos M *et al*, 2007

Primary Therapy : EN v Steroids in CD Clinical Trials





Evidence – inducing remission



- In Japan used first line with good success¹²
- Overall remission rate with liquid diets ~ 60% similar to that found with pharmacological alternatives 5-ASAs/aminosalicylates & substantially higher than placebo response¹³
- Compliance an issue remission rate of 85% with well-supported compliant patients on an elemental diet¹⁴

¹² Matsui T *et al*, 2005
¹³Gassull MA *et al*, 2001
¹⁴Teahon K *et* al, 1990

Evidence - inducing remission

- Trophic effects of liquid diet on gut mucosa along with down regulation of inflammatory response^{15,16}
 - ? prolongs remission
 - Paediatric population
 - Used formula with a natural anti-inflammatory growth factor (TGF B2 - Modulin IBD, Nestle)

¹⁵Fell JM *et al*, 2000
¹⁶Borelli O *et al*, 2006



Evidence - maintaining remission



- All beneficial ^{17,18,19}
- Cochrane review may be effective but larger studies needed ²⁰

¹⁷Matsui T *et al*, 2005
¹⁸Verma S *et al*, 2000
¹⁹Takagi S *et al*, 2006
²⁰Akobeng AK & Thomas AG, 2007



Evidence – concurrent therapy



- Concurrent dietary treatment can increase medical efficacy²¹
- Used as a bridge to control symptoms before 2nd line medications such as 5-ASAs take effect
 - Supported by BSG guidelines & cochrane review^{11,22}

²¹O' Brien CJ *et al*, 1991
²² Carter MJ *et al*, 2004

Evidence - formulae



- Majority of studies comparing elemental, semi-elemental, and polymeric formulae found <u>equal efficacy</u>^{8,9,11,18,23}
 - Most studies in adults have used elemental so difficult to draw concise conclusions^{11,14,24,25}
 - One meta-analysis trend towards greater efficacy with formulas with lower content of long chain triglycerides²⁶
 - Further studies required to identify 'ideal' formula
 - Polymeric first line in practice cheaper, more palatable, lower osmolarity

²³Raouf AH *et al*, 1991
²⁴O' Morain CA *et al* 1984
²⁵Silk DAA, 1992
²⁶Middleton SJ *et al*, 1995



Patient selection

Why nutrition not steroids?



Risk-benefit of different treatment strategies

- Efficacy
 - As effective as steroids in inducing remission
 - 60-80% remission rate greater with better case selection
- Mucosal healing
 - Certain formulas anti inflammatory growth factor
- No undesirable side effects
 - Bone health and growth unaffected

Indications for using nutrition as primary treatment

- TEN may not suit all circumstances
- Careful case selection for better efficacy
 - Crohn's disease
 - Anatomic location of disease
 - Age or disease duration
 - Gap between medical treatments
 - Patient preference highly motivated
 - Paediatric population
 - During pregnancy



Patient selection²⁷



Indications

- Active disease of small or large bowel
- Childhood/adolescent
- Steroid resistant
- Steroid poorly tolerated
- Narrowing due to oedema or swelling of mucosa

• Contraindications

- Quiescent disease
- Disease affecting rectum only
- Patient unable or unwilling to comply
- Bacterial overgrowth
- Presence of fistulae or abscesses
- Presence of tight or multiple strictures

Case Study



Female, DOB: 16.08.1983 - Small bowel CD diagnosed Apr 2008

Nov 2008 - **C/o Imuran** 150mg OD po + weaning dose prednisolone 63.8kg

May 2009 - Bloating, joint pains, BO x 4/d – formed (baseline).

Dec 2009 - Distressed with bloating, nausea, & anorexia. BO x 4-5/d – formed. 62.9kg

May 2010 -Increased diarrhoea (4-8/d, no blood/mucus), nausea, abdo pain, wt loss. -Reluctant to start steroids – **c/o entocort** 9mg (reducing) 59.3kg

Case study cond			
Jun 2010 -	No improvement with entocort 6mg OD - Diarrhoea x 4/d, Wt loss, abdo pain & bloating Imp: Active Crohn's + ? stricture Work up for humira & SIFT Change entocort → prednisolone		
	Change entocont / predmisoione	58.4kg	
Jul 2010 -	Symptoms improved with prednisolone Humira postponed due to LRTI + antibx		
		62.5kg	
24th Aug 2010 -	Off steroids, symptoms returning (BO x 4-5/d nocturnal, fatigue). SIFT – NAD. C/o humira (with ongoing imuran 150mg)	and	
		63.3kg	
15 th Sept 2010 -	Diarrhoea +++ and RIF pain Humira ongoing – no symptomatic response (c/o budesonide 9mg/d	dose 2)	
	Dietitian referral for exclusive liquid diet	60.3kg	

Case study cond..

• 17th Sept 2010 – Dietetic assessment

- Reported Wt **56.9kg**, Ht 1.68m, BMI = 20.2kg/m2 (normal)
- 6.9kg wt loss over 2 years
- Symptoms BO x 2-3/d formed, abdo cramps, bloating
- Estimated Requirements = 2047kcals, 69-85g protein, 1700-1992mls
 - 10% Stress Factor & Physical Activity Level 1.4 aim weight maintenance

Treatment plan

- •Oral nutrition sipfeeds to reqs 7 bottles daily (2100kcals, 88g protein, 1400mls)
- •Oral fluids (aim ~ 600mls water or weak tea/coffee only)
- Agreed treatment period 2 weeks 27/09/10 to 11/10/10
- Vit D insufficient (43nmol/I 4/5/10); other micronutrients normal
 - <u>Note</u>: Alb = 54 (CRP 2.8)
- Supplements Calcichew D3 forte T BD, Centrum T OD, B₁₂ IM, Omega 3
- Meds Humira 40mg (~1 month now), imuran 150mg, budesonide 9 mg OD

Daily meal plan

nsta

Inst/

Morning

Afternoon

Evening



MAL 1





Case study cond..

4th Oct 2010 – Good compliance (liquid diet, humira + imuran).
 Did not take budesonide prescribed in Sept.
 Feeling very well – formed BO x 1-2/d, no
 bloating/pain – & happy to continue.

5th Oct 2010 - Humira gradually taking effect (6 wks) 60.5kg

12th Oct 2010 – **Commenced reintroduction diet** now established on medical treatment and weaned off exclusive liquid

10th Nov 2010 - Much improved - formed BO x 1/d Weaned onto normal diet – no intolerances noted Sipfeeds ongoing x1/d + humira 40mg (11wks) & imuran

63kg, BMI 22.3kg/m2





Guidelines

Consensus – exclusive liquid



- BSG guidelines 2004 ²² (British Society of Gastrenterology)
 - Liquid diets as primary therapy in active ileal, ileocolonic, or colonic CD & contraindication to or prefer to avoid corticosteroids
 - As adjunctive therapy in ileal, ileocolonic or colonic active fistulating and perianal disease
- ECCO 2006²⁸ (European Crohn's & Colitis Organisation)
 - Liquid diets only to be used as adjunctive to medical therapy except where patients decline other drug therapy. Do not recommend in corticosteroid refractory or dependent disease.

Consensus – exclusive liquid




- ESPEN 2006²⁹ (European Society of Enteral & Parenteral Nutrition)
 - In paediatrics, nutrition therapy as first line
 - <u>In adults</u>, use enteral nutrition as sole therapy for the acute phase mainly when treatment with corticosteroids is not feasible (Grade A)
 - No significant difference in the effect of free amino acid, peptidebased, and whole protein formulae (Grade A)
 - No clear benefits for omega 3, glutamine, TGF-B enriched formulae (Grade A)

²⁹Lochs *et al*, 2006

Mechanisms of Action?





Unknowns

- Mechanism of action?
 - Theories

• Which patients benefit most ?

- More subgroup analysis needed
- Optimal length of treatment ?
 - Min 10 days
 - Unlikely to respond if still symptomatic in 2nd week ²⁷
- How best to reintroduce food when in remission
 - Various reintroduction diets not evidence based



Parenteral nutrition



• ESPEN PN guidelines 2009 ³⁰

- PN should <u>not</u> be used as primary treatment of inflammatory luminal Crohn's Disease. Bowel rest has not been proven to be more efficacious than nutrition per se (Grade A)
- The most common indication is the presence of short bowel syndrome (Grade B)
- Indicated for those who are malnourished, have inadequate or unsafe oral intake, or a non functionning, inaccessible or perforated gut. Specific indications – obstruction, high intestinal or fistulae output (Grade B)
 - Supported by BSG guidelines 2004 'Enteral nutrition is preferred (Grade C)'

³⁰Van Gossum A *et al*, 2009

Future



Nutrigenomics

- Interplay between genes and diet
- ? more targeted & individualised treatment

Role of specific nutrients

- Probiotics & prebiotics, omega 3 fatty acids, polyphenols
- Emerging evidence but roles yet to be elucidated

Solutions

• Can nutrition be used to treat active IBD?

- Yes Crohn's disease only
 - First line in paediatrics
 - Better efficacy in certain adult cases

• What are the important nutritional issues?

- Identifying risk of malnutrition
 - Consider disease phase & location/surgical history
- Setting goals of nutritional intervention
 - Adjunct, primary or concurrent?



Conclusions



- Nutrition status varies according to disease phase and malnutrition is not always overt
- Nutrition is a viable treatment option for certain subgroups with Crohn's disease
- A combination of diet and medical treatments may enhance outcome
- Require more clinical trials



- 1. Vagianos K, Bector S, McConnell J *et al*. Nutrition assessment of patients with inflammatory bowel disease. J Parenter Enteral Nutr 2007; 31:311-319.
- Lochs H, Nutritional support in IBD. In Sobotka L (ed) Basics in clinical nutrition. 3rd Edn. Prague: Galen, 2004; 314-321
- 3 Nic Suibhne *et al,* 2009
- Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J, Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002;21(1):51-57
- 5 Hass DJ, Brensinger CM, Lewis JD, Lichtenstein RA, The impact of BMI on clinical course of Crohns disease. Clinical Gastroenter Hepatol, 2006; 4(4): 428-488
- Jahnsen J, Falch JA, Mowinckel P et al. Body composition in patients with IBD
 : a population based study. American Journal of gastronterology 2003; 98(7):
 1566-1562
- Peyrin-Biroulet L, Chamaillard M, Gonzalez F *et al.* Mesenteric fat in Crohn's disease: a pathogenic hallmark or an innocent bystander? Gut 2007; 56(4): 577-83. Epub 2006 Sep 6. Review



- 8 Fernandez-Banares F, Cabre E, Gonzalez-Huix F *et al.* Enteral nutrition as primary therapy in Crohns disease. Gut. 1994; 35(1 Suppl): S55-9
- Griffiths AM, Ohlsson A, Sherman PM *et al.* Meta-analysis of enteral nutrition as a primary treatment of active crohns disease. Gastroenterology 1995; 108:1056-67
- ¹⁰ Messori A, Trallori GD, Albasio G *et al.* Defined formula diets versus steroids in the treatment of active crohns disease: a meta-analysis. Scand J Gastroenterol 1996; 31:267-72
- Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane database syst rev. 2007; 24:(1):CD000542
- 12 Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn's disease in Japan. J Gastroenterol 2005; 40 Suppl 16:25-31. Review
- Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr opin in clin nutr & meta care 2001; 4(6):561-569
- 14 Teahon K, Bjarnason I, Pearson M et al. Ten years experience with an elemental diet in the management of Crohn's disease. Gut 1990;31:1133



- 15. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharm Ther 2000; 14(3): 281-289
- 16. Borelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomised controlled open-label trial. Clin Gastro and Hepat 2006; 4(6): 744-753
- 17. Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn's disease in Japan. J Gastroenterol. 2005; 40 Suppl 16:25-31. Review.
- 18. Verma S, Brown S, Kirkwood B et al. Polymeric Vs elemental diet as primary treatment in active Crohn's disease. A randomised double-blind trial. Am J Gastroenterol 2000; 95:735-9
- 19. Takagi S, Utsunomiya K, Kuriyama S et al. Effectiveness of an half elemental diet as maintenance therapy for Crohn's disease: a randomised controlled trial. Aliment Pharmacol Therapeutics 2006; 24:1333-1340
- 20. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007; (3): CD005984. Review
- 21. O' Brien CJ, Giaffer MH, Cann PA, Holdsworth CD. Elemental diet in steroiddependent and steroid refractory Crohn's disease. Am J Gastroenterol 1991; 86(11): 1614



- 22. Carter MJ, Lobo AJ, Travis SPL, Guidelines for the management of inflammatory bowel disease in adults, Gut 2004; 53(Suppl V):v1-v16
- 23. Raouf AH, Hildrey V, Daniel J, Walker RJ, Krasner N, Elias E, Rhodes JM, Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge, *Gut 1991;32:702707 10.1136/gut.32.6.702*
- 24. O' Morain CA, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J 1984; 288:1859-62
- 25. Silk DAA, Medical management of severe inflammatory disease of the rectum: nutritional aspects. Bailleres clinical gastroenterology 1992;6(1):27-41
- ^{26.} Middleton SJ, Rucker JT, Kirby GA. Long chain triglycerides reduce efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 1995; 14(4): 229-36
- 27. King TS, Woolner JT, Hunter JO. The dietary management of Crohn's disease. Aliment Pharmacol Ther 1997; 11:17-31
- 28. Travis SPL, Stange EF, Lemann M, Oeresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel J-F, Gionchetti P, Bouhnik Y, Tiret E, Kroesen A, Starlinger M, Mortensen NJMcM for the European Crohn's and Colitis Organisation (ECCO). Gut 2006; 55 suppl 1;i16-i35
- 29. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, van Germert W, van Gossum A, Valentini L, ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr (2006), 25, 260-274
- 30. Van Gossum A, Cabre E, Hebuterne X, Jeppesen P, Zrznaric Z, Messing B, Powell-Tuck J, Staun M, Nightingale J, ESPEN guidelines on parenteral nutrition: gastroenterology. Clin Nutr (2009) 28, 415-427



Thank-you